Processa Pharmaceuticals (PCSA) said Tuesday it has entered into a binding agreement granting Intact Therapeutics an exclusive option to license PCS12852, a potential treatment for gastroparesis and other gastrointestinal motility disorders.
The agreement could provide Processa with a $2.5 million option exercise fee, up to $20 million in development and regulatory milestones, and over $432.5 million in commercial milestones, the pharmaceutical company said, adding that it will also receive a double-digit royalty on global net sales, excluding South Korea, and a 3.5% equity stake in Intact.
Processa said it must share 60% of any cash proceeds, excluding the equity stake, with its licensor, per the existing agreement.
PCS12852 showed promising safety and efficacy in a phase 2a trial for diabetic gastroparesis, the company said.
The exclusive license will be effective upon completion of definitive agreements and other closing conditions, it added.
Shares of Processa were up 208% in recent Tuesday trading.
Price: 0.69, Change: +0.47, Percent Change: +208.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。